Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients

Sponsor
Canadian Myeloma Research Group
Study ID
NCT05272826
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
65 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Iberdomide — DRUG
    Available as formulated capsules and administered as oral medication
  • Bortezomib — DRUG
    Administered as subcutaneous injection
  • Dexamethasone — DRUG
    Administered as oral medication
  • Isatuximab — DRUG
    Administered as subcutaneous injection

Study Details

This study will evaluate efficacy and tolerability of iberdomide, bortezomib, dexamethasone and isatuximab on demand administered in combination for newly diagnosed transplant-ineligible multiple myeloma patients.

Key Dates

Start date
Dec 12, 2024
Status verified
Sep 2025
Primary completion
Mar 31, 2028
Completion
Mar 31, 2031

Study Design

Enrollment
75 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Evaluate Rate of Stringent Complete Response (sCR) transplant ineligible multiple myeloma patients. [ Time Frame: After 4 cycles of therapy (each cycle is 28 days) ]

Central Contacts

Related Studies